Introduction
Diabetes mellitus represents a significant healthcare challenge in the US, with 24.7 million people with a diagnosis, leading to direct healthcare expenditure of US dollars (USD) 237 billion and USD 90 billion in lost productivity in 2017 [
1]. People with diabetes were estimated to have direct healthcare costs 2.3 times higher than people without diabetes [
1]. Choosing therapies for diabetes that are both effective and cost-effective is key to minimizing the humanistic and economic burden associated with diabetes-related complications.
Controlling blood sugar levels remains the primary aim of treatment for diabetes, with landmark studies, such as the United Kingdom Prospective Diabetes Study showing that improvements in glycemic control reduce the risk of micro- and macrovascular complications in people with type 2 diabetes [
2,
3]. The American Diabetes Association suggests a glycated hemoglobin (HbA1c) target of < 7.0% for many people with diabetes, with this individualized depending on the risk of adverse effects of treatment (such as hypoglycemia), disease duration, life expectancy, comorbidities, patient preference, and available support [
4]. Recently issued treatment guidelines suggest a more rounded, patient-centered approach to the treatment of diabetes, with all overweight or obese people with diabetes recommended to lose weight, and that the impact of medications on body weight and hypoglycemia risk should be considered [
5‐
7]. Furthermore, interventions associated with a reduced risk of cardiovascular disease as demonstrated in cardiovascular outcomes trials are preferred, particularly for patients at high risk of these events [
7].
A number of modern interventions for type 2 diabetes that continue to primarily target glycemic control, but have additional benefits by addressing other risk factors for complications are available to clinicians and patients. These include glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. GLP-1 receptor agonists, such as once-weekly semaglutide, liraglutide, exenatide and dulaglutide, have been shown to have high efficacy in terms of glycemic control, and are associated with weight loss and low risk of hypoglycemia [
6]. DPP-4 inhibitors, such as sitagliptin, are associated with intermediate efficacy in terms of glycemic control, are weight neutral and have a low risk of hypoglycemia [
6]. SGLT-2 inhibitors, such as empagliflozin, canagliflozin and dapagliflozin, are considered to have intermediate efficacy for glycemic control, and are associated with weight loss and a low risk of hypoglycemia [
6]. Oral semaglutide is the first GLP-1 receptor agonist developed for oral administration, using an absorption enhancer to facilitate absorption across the gastric mucosa [
8‐
12]. Oral semaglutide aims to provide the benefits of existing GLP-1 receptor agonists, without the requirement for daily or weekly injections.
The PIONEER trial program compared oral semaglutide with a number of interventions for type 2 diabetes, including empagliflozin 25 mg (PIONEER 2), sitagliptin 100 mg (PIONEER 3), and liraglutide 1.8 mg (PIONEER 4) [
9‐
12]. In these studies, the primary endpoint was change from baseline in HbA1c after 26 weeks of treatment evaluated by the treatment policy estimand, and oral semaglutide 14 mg was associated with a superior reduction in HbA1c compared with empagliflozin 25 mg and sitagliptin 100 mg, and a non-inferior reduction in HbA1c compared with liraglutide 1.8 mg. When change in body weight was evaluated using the treatment policy estimand, oral semaglutide 14 mg was associated with superior weight loss compared with sitagliptin 100 mg and liraglutide 1.8 mg. Across the three trials, rates of hypoglycemic events were low with oral semaglutide 14 mg, empagliflozin 25 mg, sitagliptin 100 mg and liraglutide 1.8 mg. The three trials also collected data on the proportions of patients achieving a series of treatment targets, including the single endpoints of HbA1c ≤ 6.5% and HbA1c < 7.0%, a double composite endpoint of ≥ 1.0%-point HbA1c reduction and weight loss ≥ 3.0%, and a triple composite endpoint of HbA1c < 7.0% without hypoglycemia and without weight gain. These treatment targets allow the efficacy of interventions to be assessed in a manner highly relevant to modern treatment of type 2 diabetes.
The present analysis assessed the short-term cost-effectiveness of oral semaglutide versus empagliflozin 25 mg, sitagliptin 100 mg and liraglutide 1.8 mg for treatment of patients with type 2 diabetes, in terms of the cost per patient achieving treatment targets in the US setting. The primary analyses assessed the cost per patient achieving four endpoints: (1) HbA1c ≤ 6.5%, (2) HbA1c < 7.0%, (3) ≥ 1.0%-point HbA1c reduction and weight loss ≥ 3.0%, and (4) HbA1c < 7.0% without hypoglycemia and without weight gain.
Discussion
The present analysis has demonstrated that the cost of bringing patients to four clinically-relevant endpoints was consistently lower with oral semaglutide 14 mg than with empagliflozin 25 mg, sitagliptin 100 mg and liraglutide 1.8 mg, based on data from PIONEER 2, 3 and 4, respectively. These endpoints are in line with modern treatment of type 2 diabetes, where improvements in additional parameters alongside glycemic control have been demonstrated to be important to both patients’ quality of life and long-term health [
2‐
7].
Key strengths of the present analysis can be found in the simplicity and transparency of the model, which allows inputs being readily updated to match latest unit costs and/or new clinical data. An additional strength is that no projections of long-term outcomes were made from short-term data, avoiding a common limitation of health economic analyses conducted for diabetes interventions. Nonetheless, the present analysis is designed to complement, not replace, these long-term analyses, which are pertinent for fully capturing the long-term complications associated with diabetes, which can be influenced by changes in HbA1c and additional secondary parameters [
2,
3,
7]. Previous cost of control analyses published in the US setting for GLP-1 receptor agonists once-weekly semaglutide and liraglutide have demonstrated the value of the cost of control approach, offering pertinent information to healthcare payers focused on short-term budgets [
14‐
17].
The present analysis included differing patient populations, with background diabetes therapies received varying across the PIONEER trial program. PIONEER 2 included patients only receiving metformin, while PIONEER 3 included patients receiving metformin with or without sulfonylurea and PIONEER 4 included patients receiving metformin with or without an SGLT-2 inhibitor. Oral semaglutide is the first GLP-1 receptor agonist administered orally, and therefore may potentially overcome barriers relating to therapeutic inertia. There is significant evidence that people with type 2 diabetes in the US, UK and worldwide do not intensify treatment, despite not achieving glycemic control targets, with concerns around potential side effects of therapies (such as weight gain and hypoglycemia) and fear of injection often cited as reasons for therapeutic inertia [
18‐
22]. The oral formulation of semaglutide allows people with type 2 diabetes to receive the benefits of treatment with a GLP-1 receptor agonist, such as improved glycemic control without weight gain and a low risk of hypoglycemia, without the requirement for daily or weekly injections [
9‐
11]. The present analysis demonstrated that oral semaglutide is efficacious and cost-effective in varying patient populations versus comparators for patients with type 2 diabetes receiving differing background therapies, indicating it is a viable treatment option for a variety of patients, irrespective of prior treatment.
It is important to consider the adverse events associated with new interventions. Gastrointestinal events are the most common category of adverse events with currently available GLP-1 receptor agonists, and this is also the case with oral semaglutide. Safety and tolerability of oral semaglutide were consistent with subcutaneous liraglutide 1.8 mg in the PIONEER 4 study [
9]. Data from PIONEER 3 suggest that gastrointestinal adverse events are more common with the highest dose of oral semaglutide than with the lower doses [
10].
The present analysis represents the first short-term cost-effectiveness analysis of oral semaglutide in the US, but similar studies have assessed the cost of control of other diabetes medications included in the present analysis. Liraglutide 1.2 mg and 1.8 mg were shown to be associated with a lower cost per patient achieving a target of HbA1c < 7.0% without hypoglycemia and without weight gain than sitagliptin in a 2013 study based on a head-to-head randomized controlled trial [
23]. The cost of control with liraglutide 1.8 mg and lixisenatide 20 µg was compared for five endpoints [(1) HbA1c ≤ 6.5%; (2) HbA1c < 7.0%; (3) HbA1c < 7.0% and no weight gain; (4) HbA1c < 7.0% with no weight gain and no confirmed hypoglycemia; (5) HbA1c < 7.0% with no weight gain and systolic blood pressure < 140 mmHg], with liraglutide 1.8 mg associated with a lower cost of control for all targets [
24]. A cost per response analysis evaluating the SGLT-2 inhibitors took a different approach, calculating the cost per 1% reduction in HbA1c with empagliflozin 10 mg or 25 mg (the SGLT-2 inhibitor included in the present analysis), canagliflozin 100 mg and 300 mg, dapagliflozin 5 mg or 10 mg, and in monotherapy, dual therapy with metformin, and triple therapy with metformin and sulfonylurea [
25]. This analysis found that canagliflozin 300 mg was associated with the lowest cost per 1% reduction in HbA1c at all three points in the diabetes treatment pathway, though differences in cost-effectiveness between the SGLT-2 inhibitors were small.
A limitation of the present analysis is the use of endpoints that rely on binary classification (i.e., patients did or did not reach the target). This excludes possibly substantial reductions in HbA1c levels that patients may have experienced if they did not reach the < 7.0% threshold. However, given the greater improvements in HbA1c seen with oral semaglutide throughout the PIONEER trial program, this assumption is likely to be conservative from the oral semaglutide perspective. Moreover, the use of WAC for the included medications does not reflect any rebates that might be applied for specific medical insurance companies. However, these rebates vary from payer to payer, from medication to medication (i.e., varying rebates would be applied to all interventions included in the analysis), and are confidential. Use of WAC therefore represents the best-available approach for the costs of the included interventions.
Conclusion
Oral semaglutide 14 mg represents a cost-effective treatment option versus empagliflozin 25 mg, sitagliptin 100 mg, and liraglutide 1.8 mg for bringing patients with type 2 diabetes to clinically-relevant treatment targets of a single endpoint of HbA1c ≤ 6.5%, a single endpoint of HbA1c <7.0%, a double-composite endpoint of ≥ 1.0%-point HbA1c reduction and weight loss ≥ 3.0%, and a triple-composite endpoint of HbA1c < 7.0% without hypoglycemia and without weight gain in the US.